About

Remedica - a leading Pharmaceutical Company in Cyprus

Our Vision

A healthier world through Remedica’s high quality, safe and efficacious products at affordable prices.

Our Mission

To alleviate suffering and improve the quality of human life by providing high quality, safe and efficacious pharmaceuticals and other health and care products, promptly and at a reasonable cost.

Remedica in Brief

Remedica is a leading pharmaceutical company located in Cyprus and its pharmaceutical products are distributed in more than 160+ countries worldwide. Originally founded in 1980, it went through various development stages and is now specialising in the development, production and sale of high-quality, safe and efficacious pharmaceutical products for human use. It also markets a number of other health and care products. Its pharmaceutical range consists of a product portfolio of more than 300 generic, branded generic and over-the-counter (OTC). It offers products from various therapeutic categories including antineoplastic agents, antivirals, cardiovascular, central nervous system agents, gastrointestinal agents, respiratory tract agents, dermatological agents and anti-infective products. Currently, Remedica has 5 state-of-the-art factories all of which have been inspected and approved by the health authorities of several European Union Member States including those of Cyprus, Germany and Denmark as well as those of United Kingdom, Russia, Australia (TGA), Brazil (ANVISA), Japan (PMDA), and many more.

RESEARCH AND DEVELOPMENT

Remedica devotes its entire research and development (R&D) efforts to develop innovative solutions. R&D is Remedica’s core strength and investment in it enabled the company to develop robust products for diverse markets across the world. The R & D team works to generate innovative concepts and ideas, exploiting both market needs and synergies across therapeutic areas. Even as Remedica focuses on developing new products and ideas, it continuously monitors research efficiency.

In recent years, Remedica has increased its activities by investing in the development of new pharmaceutical products. This strategy has led to a gradual but sustained rise in the number of products manufactured and has had the added benefit that innovative concepts have been able to be protected by international patents. In addition, the company can make this technology available to other companies around the world through licensing and supply agreements and the availability of these new products has allowed Remedica to penetrate more markets and broaden its customer base.

QUALITY

The quality of Remedica’s products is guaranteed by the systems operated by the Quality Control and Quality Assurance Departments that oversee all company activities which may affect the quality, safety or efficacy of its products. The Quality Control department uses specialised and advanced electronic monitoring instrumentation to impose strict controls on all stages of the production process, from the authentication of incoming raw and packaging materials to intermediates and finally to the finished products.

The Quality Assurance Department ensures that all current Good Manufacturing Practices (cGMP) are followed and makes sure that employees are trained to follow the company’s Standard Operating Procedures (SOPs), that there is a system for approving raw material suppliers; that the premises, equipment and procedures meet all the specifications based on cGMP and have been appropriately validated. In addition, the Quality Assurance Department carries out the final inspection of each batch before it is released into the market.

Remedica is not only committed to deliver quality and compliant products but also leverages its quality system and practices as a competitive advantage. The company’s long-term commitment focuses on quality and compliance. In order to guarantee quality and safety, Remedica makes sure that responsibilities and activities are clearly defined.

PRODUCTION

Remedica’s site in Limassol, Cyprus encompasses 13 buildings which occupy a total area of 50,000m2. Of these, five are manufacturing facilities so, along with the main factory which is for general use, there are 4 additional facilities designed for and dedicated to the production of a specific class of pharmaceutical product or products. Therefore, Remedica has the following 5 factories:
1. General Use
2. Penicillin derivatives
3. Cefalosporins
4. Certain hormones
5. Anti-cancer products

The above products come in a variety of dosage forms like tablets, capsules, oral liquids, gels, creams, ointments, powder syrups, topical aerosols and suppositories.

All of Remedica’s manufacturing facilities have been built in strict accordance with the latest international regulatory standards such as the current Good Manufacturing Practice (cGMP) regulations. The facilities have been inspected and approved by the health authorities of several European Union Member States including Cyprus, Germany, and Denmark as well as those of the United Kingdom, Russia, Australia (TGA), Brazil (ANVISA), Japan (PMDA) and many more.

Remedica’s large, modern warehouses and management systems have been specifically designed in order to guarantee the safe and efficient storage and distribution of raw pharmaceuticals and packaging materials, as well as semi-finished and finished products. As part of the environmental control system, temperature and relative humidity inside the warehouses are continuously monitored and controlled.

Building No.10, which was the most recent manufacturing unit to be completed, was designed for the manufacture of anti-cancer products and is the pride of Remedica representing a major investment for the company. This ultra-modern, stand-alone building houses its own production, packaging, storage, research and development facilities and, of course, auxiliary and service spaces.

Remedica Pharmaceuticals - Worldwide Presence

Remedica Worldwide

Remedica exports worldwide via a selected network of local representatives. It provides health care professionals with the necessary products to treat millions of patients